An increasing ammount of data is available in cancer research that is not yet fully used provided by the different ‘omics’ technologies (genomics, radiomics, proteomics, etc.). cancer types for diagnosis, therapy planning, response assessment and followup. We study the properties of current quantifiers of tumor properties (such as heterogeneity or morphology features) to determine which ones can be surrogates of the disease status. We also define novel ones based on mathematical models that could be used as prognostic and response biomarkers. We also study how to combine the biomarkers into more complex prognosis and predictive models.